1. Home
  2. FGEN vs CGTX Comparison

FGEN vs CGTX Comparison

Compare FGEN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • CGTX
  • Stock Information
  • Founded
  • FGEN 1993
  • CGTX 2007
  • Country
  • FGEN United States
  • CGTX United States
  • Employees
  • FGEN N/A
  • CGTX N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGEN Health Care
  • CGTX Health Care
  • Exchange
  • FGEN Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • FGEN 34.5M
  • CGTX 30.0M
  • IPO Year
  • FGEN 2014
  • CGTX 2021
  • Fundamental
  • Price
  • FGEN $0.55
  • CGTX $0.59
  • Analyst Decision
  • FGEN
  • CGTX Strong Buy
  • Analyst Count
  • FGEN 0
  • CGTX 6
  • Target Price
  • FGEN N/A
  • CGTX $8.30
  • AVG Volume (30 Days)
  • FGEN 753.5K
  • CGTX 821.4K
  • Earning Date
  • FGEN 02-24-2025
  • CGTX 03-25-2025
  • Dividend Yield
  • FGEN N/A
  • CGTX N/A
  • EPS Growth
  • FGEN N/A
  • CGTX N/A
  • EPS
  • FGEN N/A
  • CGTX N/A
  • Revenue
  • FGEN $180,015,000.00
  • CGTX N/A
  • Revenue This Year
  • FGEN $21.91
  • CGTX N/A
  • Revenue Next Year
  • FGEN N/A
  • CGTX N/A
  • P/E Ratio
  • FGEN N/A
  • CGTX N/A
  • Revenue Growth
  • FGEN 16.15
  • CGTX N/A
  • 52 Week Low
  • FGEN $0.18
  • CGTX $0.34
  • 52 Week High
  • FGEN $2.80
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 58.51
  • CGTX 39.91
  • Support Level
  • FGEN $0.46
  • CGTX $0.57
  • Resistance Level
  • FGEN $0.51
  • CGTX $0.68
  • Average True Range (ATR)
  • FGEN 0.04
  • CGTX 0.06
  • MACD
  • FGEN 0.00
  • CGTX -0.02
  • Stochastic Oscillator
  • FGEN 72.57
  • CGTX 7.83

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: